Exchange cooperation | To create a new form of cell therapy industry based on retroviral vector, our chief scientist Professor Wang Jianxun and his delegation visited Nanjing Beishhundsun Biological T
On the afternoon of March 10, our chief scientist Professor Wang Jianxun, Vice Minister of Research and Development Sun Rui, and Yang Bolui, executive president of Junhou Biology, a subsidiary of our company, visited Nanjing North Hundsun Biological Technology Co., LTD., and Dr. He Xiaohong, founder of North Hundsun Biological, warmly received and held a symposium.
At the symposium, Professor Wang Jianxun, chief scientist of Shenzhen Cell Valley, introduced the business scope of Shenzhen Cell Valley and the existing R&D and production pipelines, including the technological breakthrough of the retroviral vector, the construction of the platform to assist the declaration, and the improvement of the GMP talent training mechanism. At the same time, he took advantage of the geographical advantages of the Greater Bay Area. Establish in-depth cooperation with a number of clinical research institutions, scientific research institutions, testing institutions, review institutions and pharmaceutical companies in South China. Chief scientist Wang Jianxun said that Beihundsen is currently the leader in the development of universal CAR-T in China, and Shenzhen Cell Valley is willing to join forces with the Beihundsen team to jointly link the Guangdong-Hong Kong-Macao Greater Bay Area and the Yangtze River Delta region, and work together to create a new form of cell therapy industry based on retroviral vectors.
Dr. He Xiaohong, the founder of North Hundsun Material, gave a comprehensive introduction to North Hundsun Material from the aspects of enterprise organizational framework, R&D pipeline, etc., and said that North Hundsun Material is committed to the original innovation of universal CAR-T, has a strong R&D strength and R&D team, and has been deeply engaged in the field of U CAR-T for many years, and there is a U CAR-T in IND clinical trial stage. The product is currently used as a viral vector for the lentivirus vector, but Shenzhen Cell Valley has the advantages of the industrialization of retroviral vector production, in the future research and development pipeline will try to reverse the virus vector, if the two sides cooperation will be win-win, its advantages not only in the cell product preparation stage, but also reflected in the IND application and drug approval process. The two sides from the retroviral vector production cost advantages, production and quality system architecture, clean room and other hardware conditions and other aspects of the heated discussion, the two sides said that in the future to make good use of their own advantages, resource integration, to create a whole chain industry, promote the domestic retroviral vector-based cell products innovation, leading the world!
